[July 17, 2014]

Research and Markets: HIV Therapeutics in Major Developed Markets 2014-2019

Research and Markets (http://www.researchandmarkets.com/research/dsn4k9/hiv_therapeutics) has announced the addition of the "HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth" report to their offering.

Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth

The HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012-2019 forecast period to reach $16.3 billion

'HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth' provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the majr marketed products, as well as insights into the HIV therapeutics R&D pipeline.

The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development.

Scope

• A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosisIn-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
• Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
• Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy, Spain and Canada
• Discussion of the drivers and barriers for market growth

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Disease Introduction

3 Marketed Products

4 Pipeline for HIV

5 Market Forecast to 2019

6 Deals and Strategic Consolidations

7 Appendix

For more information visit http://www.researchandmarkets.com/research/dsn4k9/hiv_therapeutics

[ Back To TMCnet.com's Homepage ]